Gilead Sciences Inc
NASDAQ:GILD

Watchlist Manager
Gilead Sciences Inc Logo
Gilead Sciences Inc
NASDAQ:GILD
Watchlist
Price: 90.19 USD 0.48% Market Closed
Market Cap: 112.4B USD
Have any thoughts about
Gilead Sciences Inc?
Write Note

Operating Margin
Gilead Sciences Inc

38.4%
Current
38%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
38.4%
=
Operating Profit
10.9B
/
Revenue
28.3B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Gilead Sciences Inc
NASDAQ:GILD
112.2B USD
38%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
314.7B USD
28%
US
Amgen Inc
NASDAQ:AMGN
157B USD
19%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
133.6B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.5B EUR
-22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
31.5B USD
-9%
Country US
Market Cap 112.2B USD
Operating Margin
38%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 314.7B USD
Operating Margin
28%
Country US
Market Cap 157B USD
Operating Margin
19%
Country US
Market Cap 115.9B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 133.6B AUD
Operating Margin
26%
Country US
Market Cap 82.6B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 34.5B EUR
Operating Margin
-22%
Country US
Market Cap 31.5B USD
Operating Margin
-9%
No Stocks Found

Gilead Sciences Inc
Glance View

Market Cap
112.4B USD
Industry
Biotechnology

Gilead Sciences Inc. is a biopharmaceutical company that has carved a significant niche in the healthcare industry by focusing on the discovery, development, and commercialization of innovative medicines. Founded in 1987 and based in Foster City, California, Gilead has gained prominence for its groundbreaking antiviral therapies, particularly in the field of HIV and hepatitis C. The company transformed the landscape of these diseases with its flagship products, among them Truvada and Harvoni, which have been instrumental in improving patient outcomes and generating substantial revenues. Gilead continues to build on its legacy by expanding its research into oncology, inflammatory diseases, and cardiovascular conditions, positioning itself as a leader in addressing some of the world's most pressing health challenges. For investors, Gilead Sciences represents a compelling opportunity amid a rapidly evolving pharmaceutical market. The company’s robust pipeline of candidates and ongoing research into novel therapeutic areas suggest potential for sustained growth and profitability. With a strong commitment to innovation, Gilead is not only focused on maximizing the utility of its existing treatments but is also exploring partnerships and acquisitions to bolster its drug development capabilities. As the global demand for effective treatments rises, Gilead stands to benefit from its established reputation, financial resilience, and strategic investments, making it a noteworthy consideration for those looking to invest in a company that is dedicated to improving health outcomes worldwide.

GILD Intrinsic Value
89.71 USD
Overvaluation 1%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
38.4%
=
Operating Profit
10.9B
/
Revenue
28.3B
What is the Operating Margin of Gilead Sciences Inc?

Based on Gilead Sciences Inc's most recent financial statements, the company has Operating Margin of 38.4%.